Genmab Trial Reports 50% Lower Risk of Death in Interim Analysis
The petosemtamab and pembrolizumab combination met both primary endpoints in a Phase 3 trial of PD-L1-positive head and neck cancer.
Makkler Newsroom · Oct 29, 03:07 AM · 1 min read
Market closed· · DKK · Data may be delayed
Avg. target DKK 4,394.70 (+25.5%)
Prices may be delayed and are for informational purposes only - not investment advice.
The petosemtamab and pembrolizumab combination met both primary endpoints in a Phase 3 trial of PD-L1-positive head and neck cancer.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.